CONSOLIDATED FINANCIAL REPORT
For the Third Quarter of Fiscal 2013
(Fiscal Year Ending March 31, 2014, Japan GAAP)

February 3, 2014

Eisai Co., Ltd. — Stock exchange listing: Tokyo
TSE Code: 4523 — URL: http://www.eisai.com
Representative: Haruo Naito, President & CEO
Contact: Sayoko Sasaki, Vice President, Corporate Affairs — Telephone: +81-3-3817-5120

Expected date of quarterly report submission:	February 13, 2014
Expected date of dividend payment commencement:	-
Preparation of quarterly supplementary explanatory material:	Yes
Quarterly results briefing held:	Yes

(Figures are rounded down to the nearest million yen unless otherwise stated.)

1. Consolidated Financial Results for the Third Quarter of Fiscal 2013 (April 1, 2013 to December 31, 2013)

(1) Consolidated Operating Results (cumulative)

(Percentage figures show year-on-year change.)

	Net sales		Operating income		Ordinary income		Net income	
	(¥ million)	%	(¥ million)	%	(¥ million)	%	(¥ million)	%
3Q Fiscal 2013	448,047	3.8	42,825	-20.9	39,232	-21.9	29,492	-13.3
3Q Fiscal 2012	431,553	-14.5	54,125	-34.2	50,224	-35.5	34,011	-30.9

(Note) Comprehensive income:ve inr3e6 35.76 14.6* nBT6002 0.958e6 35.7611.19 3595(i)22(n)3(r)26(3e6 35.7611.197 354.53 0999 1

2. Dividends

	Annual dividend per share				
	1Q end	2Q end	3Q end	Year-end	Total
	(¥)	(¥)	(¥)	(¥)	(¥)
Fiscal 2012	-	70.00	-	80.00	150.00
Fiscal 2013	-	70.00	-		
Fiscal 2013 (Forecast)					

Supplementary Materials

Table of Contents

(

1.

Comprehensive income, after adding/deducting minority interests and other comprehensive income to/from net income, was ¥77,393 million (up 51.4% year on year), aided in part by foreign currency translation adjustments due to the depreciation of the yen.

[Cash Income]

The Group uses cash income as a managerial index to express its ability to generate cash. Cash income is the total amount of cash available for investment in future growth, return to shareholders, repayment of borrowings and other necessary payments. The Group considers cash income as an indicator to assess corporate growth potential and strategies.

Net income was ¥29,492 million; depreciation of property, plant and equipment and amortization of intangible assets was ¥29,294 million; amortization of goodwill was ¥7,032 million; and

was launched in June 2013.

Americas Pharmaceutical Business

Net sales totaled ¥106,811 million (down 6.7% year on year). Segment profit decreased to ¥9,346 million (down 63.6% year on year) due to aggressive investment in new products.

Net sales of Aciphex decreased to ¥33,380 million (down 11.7% year on year) due to the expiration of composition-of-matter patents. Net sales of Aricept came to ¥3,803 million (down 59.3% year on year), while net sales of Halaven increased to ¥9,912 million (up 16.1% year on year). Net sales of Belviq, an antiobesity agent launched in the United States in June 2013, came to ¥1,663 million.

The antiepileptic drug Fycompa was lau9 66951..904le8

59

Net sales of the Chocola BB group of products came to ¥9,227 million (up 6.8% year on year), owing to strong sales of drink products.

2) Research & Development Pipeline, Alliances, and Other Events

Status of Ongoing Research & Development Pipelines

The anticancer agent Halaven (eribulin mesylate) obtained approval as a treatment for breast cancer sequentially around the world and as of January 2014 is approved in 52 countries worldwide. Furthermore, a Phase III study in non–small cell lung cancer is being conducted in the United States, Europe and Asia, including Japan. Furthermore, a Phase III study to investigate the agent as a potential treatment for sarcoma is underway in the United States, Europe and Asia, while a Phase II study is ongoing in Japan. Based on the study results obtained from a Phase III study in the United States and Europe that evaluated Halaven as a potential second-line chemotherapy for the treatment of breast cancer, the Group submitted an application to the European Medicines Agency (EMA) in April 2013 seeking approval for an additional, earlier-line indication and the EMA has accepted the application for review. A Phase III study to investigate the agent as a potential first- or second-line chemotherapy for HER2-negative breast cancer has been initiated in the United States. A Phase III study to investigate the agent as a potential third-line chemotherapy for breast cancer has been initiated and is underway in China.

The AMPA receptor antagonist Fycompa (perampanel) was approved by the European Commission (EC) in July 2012 as an adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy aged 12 years and older. The agent obtained approval for the same indication by the Food and Drug Administration (FDA) in the United States in October 2012. As of January 2014, Fycompa is approved in 36 countries worldwide. A Phase III study for the same indication is ongoing in Asia, including Japan and China. A Phase III study of the agent as an adjunctive therapy for the treatment of generalized seizures in patients with epilepsy is underway in the United States, Europe sd in 3

In October 2013, the Company received additional indication approval from the EC regarding the use of Zonegran (zonisamide) as an adjunctive treatment for partial seizures in pediatric patients aged 6 years and above in Europe.

In October 2013, the Company submitted an application for an additional indication in Japan regarding the use of anti-Alzheimer's disease agent Aricept (donepezil hydrochloride) in the treatment of dementia with Lewy bodies.

The Company received a non-approval letter from the Chinese regulatory authority for clevudine (generic name) regarding its use in the treatment of patients with chronic hepatitis B. Plans for future development of the compound are currently under review.

In November 2013, the Company submitted an application for the proton pump inhibitor Pariet in Japan seeking a further indication expansion for use in the prevention of recurrence of gastric and duodenal ulcers during treatment with low-dose aspirin and the approval of a new 5 mg tablet formulation.

In January 2014, the Company submitted an application seeking regulatory approval in Japan for an additional pediatric fine-granule formulation of anti-tachyarrhythmia treatment Tambocor. Previously, Eisai had successfully applied for additional indication and dosage and administration of Tambocor in Japan for pediatric use, based on a request received from the Council for Pediatric Pharmacotherapy of the Japanese Ministry of Health, Labour and Welfare (MHLW).

Proof of Concept (POC, validation of the concept of drug discovery) of the anticancer agent E7080 (lenvatinib mesylate) on melanoma has been achieved in a joint development program being conducted as part of the Company's strategic collaboration with Quintiles (U.S.). Based on th7 TmS.

A Phase III study to investigate the thrombopoietin receptor agonist E5501 as a potential treatment for thrombocytopenia in chronic liver disease requiring surgery has been initiated in the United States, Europe and Asia.

A Phase II study of the anti-insomnia agent E2006 has been initiated in the United States.

The investigational anticancer agent E7080 showed a highly statistically significant improvement in progression-free survival (PFS), the primary endpoint, in the preliminary result of a Phase III study in patients with radioiodine-refractory differentiated thyroid cancer. Based on this result, the Company plans to file an application for approval of this agent with regulatory authorities in Japan, the United States and Europe.

Status of Major Alliances and Agreements

In April 2013, the Company's Japan Sales & Marketing organization and management structure underwent a transformation with the aim of more accurately understanding the needs and behavior of patients seeking medical consultation and enhancing activities that increase patient satisfaction. A two-unit structure has now been introduced comprising an Oncology *hhc* Unit staffed by

In July 2013, the Company entered into a share transfer agreement with Lawson, Inc. (Tokyo) concerning the transfer to Lawson, Inc. of all shares of consolidated subsidiary Eisai Seikaken Co., Ltd. held by the Company (70% of total shares issued). All transfer procedures were completed on August 30, 2013.

In August 2013, the liquidation proceedings of the Company's diagnostics research and development subsidiary Palma Bee'Z Research Institute Co., Ltd., which had been conducted as part of the Group's efforts to go ahead with the transformation of its *in vitro* diagnostics development function, was completed.

In August 2013, the Company received prequalification from the World Health Organization (WHO) for diethylcarbamazine citrate (DEC) 100 mg tablets produced at its Vizag Plant in India for the treatment of lymphatic filariasis. The free supply of DEC tablets to WHO began in October 2013.

In August 2013, the Company entered into a community development partnership agreement with the City of Yokohama in Kanagawa, Japan, with the aim of promoting local dementia support initiatives. Based on the agreement, the Company will be working closely with the City to promote a wider understanding of dementia and awareness on the human rights of individuals living with the disease as well as support cooperation among local government, medical, care and other agencies.

In September 2013, the Company's U.S. research subsidiary H3 Biomedicine Inc. entered into a collaborative agreement with Selvita S.A. (Poland), one of the largest drug discovery companies in Eastern Europe, to create novel anticancer agents. Under the agreement, both companies will seek to create novel anticancer agents through identification and validation of several kinases as therapeutic targets for cancers with specific genetic characteristics.

In October 2013, the Company's subsidiary in the United States, Eisai Inc., decided to increase the number of sales representatives in charge of providing information about the antiobesity agent Belviq (lorcaserin hydrochloride) by more than 200 contract employees by December 2013, making the total number of sales representatives about 400 personnel.

In

3) Explanations Concerning Consolidated Financial Position

Assets, Liabilities and Equity

Total assets as of the end of the period amounted to ¥978,751 million (down ¥11,497 million from the end of the previous fiscal year). This decrease in total assets was primarily attributable to the decrease in short-term investments, the decrease in cash and deposits used for redemption of bonds and debentures, and the repayment of long-term borrowings.

Total liabilities as of the end of the period amounted to ¥470,502 million (down ¥45,443 million from the end of the previous fiscal year).

Total equity as of the end of the period amounted to ¥508,249 million (up ¥33,945 million from the end of the previous fiscal year) due to an increase in equity of overseas subsidiaries in yen resulting from exchange rate fluctuations. As a result, the shareholders' equity ratio as of the end of this period came to 51.5% (up 4.1 percentage points from the end of the previous fiscal year), while the net debt equity ratio (Net DER) as of the end of this period was 0.21 (down 0.06 points e

4) Basic Policy Concerning Profit Allocation and Dividend Forecast for End of Fiscal 2013

The Company

5) Explanations Concerning Consolidated Financial Forecasts for Fiscal 2013

from the previous forecast). Net income excluding the impact of tax rate changes and expenses related to the above-mentioned structural reform increased by ¥2,200 million compared to the net income recorded in fiscal 2012 and is expected to come to ¥50,500 million (up 4.6% year on year).

The forecast for cash income excluding the above-mentioned structural reform–

2. Explanatory Notes in Financial Results Summary

1) Changes in Number of Significant Subsidiaries during

3. Consolidated Financial Statements

1) Consolidated Balance Sheet

(millions of yen)

Assets		
Current assets		
Cash and deposits	88,669	94,283
Notes and accounts receivable-trade	185,486	186,735
Short-term investments	98,788	66,984
Merchandise and finished goods	54,860	57,737
Work-in-process	17,816	16,587
Raw materials and supplies	14,944	16,123
Deferred tax assets	47,094	48,573
Other	23,185	18,875
Allowance for doubtful accounts	(117)	(118)
Total current assets	530,727	505,782
Noncurrent assets		
Property, plant and equipment		
Buildings and structures—net	85,907	88,546
Other—net	56,341	54,206
Total property, plant and equipment	142,248	142,753
Intangible assets		
Goodwill	127,342	135,267
Sales rights	51,432	53,083
Core technology	43,724	46,249
Other	13,546	12,161
Total intangible assets	236,046	246,763
Investments and other assets		
Investment securities	34,293	32,712
Deferred tax assets	40,727	43,804
Other	6,339	7,043
Allowance for doubtful accounts	(133)	(108)
Total investments and other assets	81,226	

2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income

(Consolidated Statement of Income)

(Consolidated Statement of Comprehensive Income)

(millions of yen)

Income before minority interests	34,230	29,681
Other comprehensive income (loss)		
Valuation difference on available-for-sale securities	(418)	906
Deferred gain (loss) on derivatives under hedge accounting	(9)	235
Foreign currency translation adjustments	17,310	46,570
Total other comprehensive income (loss)	16,882	47,712
Comprehensive Income (loss)	51,112	77,393
(BreakdowBT1 0 0 125(s829(h)-2f*BT/F2 9.025 Tf1 0 44.402 Tm25 reW* n0 44.402 T4 13.552 737)-25(0)] TJET8770		

3) Consolidated Statement of Cash Flows

4) Notes Concerning Consolidated Financial Results

(Going Concern)

Not applicable

(Note Regarding Significant Changes in the Amount of ShareholdersôEquity)

Not applicable

(Additional Information)

I. Business Divestiture

I. Third Quarter of Fiscal 2012 (April 1, 2012 to December 31, 2012)

(1) Information concerning sales and profit (loss) by reporting segment

(millions of yen)

	Reporting segment[1]						Other[2]	Total
	Pharmaceutical Business							
	Japan	Americas	Asia	EMEA	CHB—Japan	Sub-total		
Net sales to external customers	234,192	114,460	29,670	18,897	15,844	413,065	18,487	431,553
Segment profit	102,870	25,689	6,090	1,285	2,936	138,872	9,177	148,050

(Notes) 1 Major countries, regions or businesses included in each(r b)-5(u)-3(s)-ere in-6(n)9(cb)-5(u)-17.98 0.48 15 reP4-6(,)-3(r)-13

II. Third Quarter of Fiscal 2013 (April 1, 2013 to December 31, 2013)

(1) Information concerning sales and profit (losr

Consumer Healthcare Business　Japan (mainly OTC drugs).

In line with this organizational reform, the Group has changed the designation of its reporting segments, with changes also being reflected in segment information for the third quarter of fiscal 2012.

(4) Information concerning loss on impairment of noncurrent assets and goodwill by reporting segment

c. Application Period: